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Background: Reduced membranous expression of the cytoskeleton-associated protein ezrin has previously been
demonstrated to correlate with poor prognosis in urothelial bladder cancer in several independent studies. The
present study provides a first description of clinicopathological characteristics of incident urothelial cancers, not only
located to the bladder, in the prospective, population-based cohort study Malmö Diet and Cancer. In addition, the
prognostic value of ezrin expression is validated in primary tumours, and the longitudinal expression of ezrin
examined in a subset of primary and recurrent tumours (n = 28).
Methods: Among a total number of 355 incident tumours registered up until Dec 31 2010, 335 were located to
the bladder. Immunohistochemical expression of cytoplasmic and membranous ezrin was evaluated in tissue
microarrays with primary tumours from 272 cases and recurrent tumours from 28 cases. A combined score of the
minimum, mean and maximum fraction and percentage of staining was calculated. Classification regression tree
analysis was applied for selection of prognostic cutoff. Kaplan-Meier analysis, log rank test, univariable and multivariable
Cox regression proportional hazards’ modeling were used to evaluate the impact of ezrin expression on 5-year overall
survival (OS).
Results: Ezrin expression could be evaluated in 263/272 primary and all 28 recurrent tumours. Membranous but not
cytoplasmic ezrin was significantly reduced in recurrent compared to primary tumours (p < 0.001). Low cytoplasmic
and membranous ezrin expression were associated with more advanced T-stage (p = 0.004, p < 0.001) and high-grade
tumours (p = 0.025, p < 0.001), but not with age, sex, tumour location or smoking status. Both low cytoplasmic and
membranous ezrin staining were associated with a significantly reduced 5-year OS (HR = 1.65; 95% CI 1.06-2.57 and
HR = 2.51, 95% CI 1.52-4.17), but only low membranous ezrin remained prognostic after adjustment for age, sex, stage,
grade and smoking status (HR = 1.69, 95% CI 1.00-2.85).
Conclusions: This study provides a first description of the clinicopathological characteristics of 355 incident urothelial
cancers in the Malmö Diet and Cancer Study up until 2010. In addition, the value of ezrin expression as a prognostic
biomarker is further consolidated in this type of cancer.
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Urothelial carcinoma (UC) or transitional cell carcinoma
may arise anywhere in the urothelial tract from the renal
pelvis to the urethra, with the majority of cases occur-
ring in the urinary bladder [1]. Urinary bladder cancer
makes up for the fifth most common cancer diagnosis in
developed countries [2]. Despite the higher prevalence
in men, studies have demonstrated that women are at
greater risk of presenting with more advanced disease
and have a worse prognosis [3]. Tobacco smoking is the
leading cause of urothelial cancer [4], and other risk fac-
tors are occupational exposure to e.g. aromatic amines
and polycyclic aromatic hydrocarbons [5], and family
history [6]. An influence of dietary factors, e.g. high fat
intake, has also been suggested [7].
Non-muscle invasive tumours of the bladder, i.e. tu-
mours in stage Ta, T1 and carcinoma in situ (CIS or
Tis) make up for about 75% of the primary diagnoses
and are commonly treated with transurethral resection
of the bladder (TURB) and/or intravesical instillation of
Bacillus Calmette-Guérin (BCG), with the purpose to
treat existing tumour as well as to prevent recurrence
and progression [8]. Nevertheless, recurrent disease is a
frequent phenomenon and the risk of progression into
muscle-invasive disease remains unpredictable [9,10].
Thus, there is a great need for better prognostic tools in
order to identify high-risk categories of non-muscle in-
vasive tumours, which should be treated with early rad-
ical cystectomy. Muscle-invasive tumours, e.g. in stage
T2 and beyond, are treated with radical cystectomy,
neoadjuvant chemotherapy or both [11]. The efficacy of
available chemotherapeutic is however variable, and
there is also a need for better treatment predictive bio-
markers in order to improve response rates for patients
with advanced bladder cancer.
Despite a plethora of proposed biomarkers, none have
yet been implemented into clinical protocols for the
management of urothelial cancer. In a first study from
2009, Palou et al. found that reduced membranous ex-
pression of the membrane-cytoskeletal linking protein
ezrin was associated with adverse tumour characteristics
and a worse prognosis in 92 patients with T1G3 urothe-
lial cell carcinoma of the bladder [12]. Another recent
study on 104 bladder cancer cases of varying stages and
grades, loss of membranous ezrin was found to correlate
with adverse tumour characteristics, but the prognostic
impact was not evaluated [13]. The prognostic value of
ezrin expression was however confirmed in a recent
study by our group, encompassing two independent
patient cohorts, n = 100 and n = 342, respectively [14].
The purpose of this study was to provide a first
description of incident UC cases in the Malmö Diet and
Cancer Study (MDCS) up until December 31 2010, and
to further validate the expression, clinicopathologicalcorrelates and prognostic significance of ezrin in UC,
not only limited to the bladder. Moreover, a longitudinal
study of ezrin expression was performed in a small series
(n = 28) of paired primary and recurrent UC samples.Methods
Study group
Between 1991 and 1996, a total number of 28 098 indi-
viduals; 11 063 (39.4%) men and 17 035 (60.6%) women,
between 44–74 years were enrolled in the prospective,
population-based cohort study Malmö Diet and Cancer
Study (MDCS), from a background population of 74 138
[15]. All participants completed the baseline examin-
ation, which included a questionnaire, anthropometric
measurements and a dietary assessment. The question-
naire covered information on physical activity, use of
tobacco and alcohol, heredity, socio-economic factors,
education, occupation, previous and current disease and
current medication. In addition, blood samples were
collected and stored in −80°C. Follow-up is performed
annually by record-linkage to national registries for
cancer and cause of death.
Until end of follow-up 31 December 2010, a total
number of 367 incident cases of UC had been registered
in the MDCS. All tumours were histopathologically re-
evaluated and classified according to the WHO grading
system of 2004 by a board certified pathologist. Twelve
(3.3%) cases were misclassified, rendering a total number
of 355 incident cases, of which 350 (98.6%) had available
pathology records as well as archival specimens. Of the
re-evaluated tumours, 78 (22.3%) cases were excluded
from tissue microarray (TMA) construction due to an
insufficient amount of tumour tissue (n = 70), or only cy-
tology or autopsy specimens available (n = 8), rendering
a total number of primary tumours from 272 cases
eligible for TMA construction. A flowchart describing
the cohort is provided in Figure 1.
Ethical permissions for the MDCS (Ref. 51/90), and
the present study (Ref. 530/2008), were obtained from
the Ethics Committee at Lund University.Tissue microarray construction
TMAs were constructed as previously described [14,16]
using a semi-automated arraying device (TMArrayer,
Pathology Devices, Westminister, MD, USA). For longi-
tudinal analysis of biomarker expression, an additional
TMA with matched samples from recurrent tumours
was constructed from 28 cases, 21 (75.0%) of which were
local, 4 (14.3%) regional (lymph node), and 3 (10.7%)
distant recurrences. All recurrent tumours were chemo-
naive according to the pathology protocols. All primary
and recurrent tumour samples were represented in
duplicate tissue cores (1 mm).
Figure 1 Flowchart of urothelial cancers in the Malmö Diet and Cancer cohort. A flowchart outlining the study cohort from a total number
of 367 registered incident cases up until December 31st 2010.
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For immunohistochemical analysis, 4 μm TMA-sections
were automatically pre-treated using the PT Link system
and then stained in an Autostainer Plus (DAKO; Glostrup,
Copenhagen, Denmark) with a polyclonal, monospecific
antibody (HPA021616, Atlas Antibodies AB, Stockholm,
Sweden), diluted 1:1500. The specificity of the antibody
has been confirmed by immunofluorescence, Western
blotting and protein arrays (www.proteinatlas.org). Ezrin
expression was annotated in accordance with previous
studies [14], however using a further refined system. For
evaluation of cytoplasmic staining, the percentage of cells
with stained cytoplasm was denoted for each core, with a
minimum value of 10% of a specific intensity needed in
order to be accounted for, and also the proportion of cells
with each degree of intensity (0–3), in percent. For ex-
ample 10% cells with intensity 1, 40% with intensity 2 and
50% with intensity 3, were denoted as 0,1*1 + 0,4*2 + 0,5*3
for each given core. For evaluation of membranous ezrin,
the percentage of cells with membranous staining was de-
noted (at least 5% for consideration), as well as the inten-
sity of the staining (with a minimum proportion of 10% of
a specific intensity required in order to be accounted for).
The minimum, mean and maximum cytoplasmic and
membranous ezrin expression was calculated from each
tumour, based on their respective mean value of the
annotated cores. The staining was evaluated by three
independent observers, including one board certified
pathologist, who were blinded to clinical and outcomedata and every sample was re-evaluated once. Omission
of primary antibody was used as a negative control,
normal colonic mucosa as positive external control and
lymphocytes as an internal positive control. Discrepant
cases were re-evaluated once again and discussed in
order to reach consensus.
Statistical methods
Non-parametric Mann–Whitney U or Kruskal-Wallis tests
were applied for analysis of the correlations between
minimum, mean and maximum cytoplasmic and ezrin
expression and clinicopathological characteristics. Wilcoxon-
rank sum test was applied for comparison of ezrin ex-
pression in primary and recurrent tumours. Classifica-
tion and regression tree (CRT) analysis was applied to
assess optimal prognostic cut-offs for mean cytoplasmic
and membranous ezrin expression. Receiver operating
characteristics (ROC) curve analysis was also applied to
verify the CRT-derived cutoffs. Kaplan-Meier analysis
and log rank test were used to illustrate differences in
five-year OS according to high and low ezrin expression.
Cox regression proportional hazards modeling was used to
estimate the impact patient and tumour characteristics on
OS and of ezrin expression on five-year OS in both univari-
able and multivariable analysis, adjusted for age, sex, T-
stage, grade and smoking history. All tests were two sided.
P-values <0.05 was considered significant. All statistical
analyses were performed using IBM SPSS Statistics version
20.0 (SPSS Inc., Chicago, IL, USA).
Table 2 Patient and tumour characteristics in the entire
incident cohort, and in cases with tumours included and








n (%) 355 (100) 272 (76.6) 83 (23.4)
Age 0.908
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Distribution of risk factors in cases and rest of cohort
The distribution of established risk factors of urothelial
cancer for incident cases and rest of cohort is presented
in Table 1. Age at baseline, the proportion of men and
smokers was significantly higher in cases than in rest of
cohort.Mean,
median
71.4, 71.7 71.4, 71.5 71.4, 72.2
Range 51.2-86.6 51.2-86.8 56.3-84.2
Sex 0.895
Women 109 (30.7) 84 (30.9) 25 (30.1)
Men 246 (69.3) 188 (69.1) 58 (69.9)
T stage <0.001
pTa 163 (45.9) 116 (42.6) 47 (67.1) ¶<0.001
pT1 97 (27.3) 86 (31.6) 11 (15.7)
pT2 64 (18.0) 64 (23.5) 0 (0.0)
pT3 1 (0.3) 1 (0.4) 0 (0.0)
pT4 5 (1.4) 5 (1.8) 0 (0.0)
CIS 12 (3.5) 0 (0.0) 12 (17.1)
Missing 13 0 13
Grade <0.001
Low 183 (51.5) 136 (50.0) 47 (77.0)
High 150 (42.3) 136 (50.0) 14 (23.0)
Missing 22 0 22
Location 0.108
Bladder 335 (95.7) 264 (97.1) 71 (91.0)
Urether 9 (2.6) 4 (1.4) 5 (6.4)
Urethra 1 (0.3) 1 (0.4) 0 (0.0)
Renal pelvis 5 (1.4) 3 (1.1) 2 (2.6)Clinicopathological characteristics
Patient and tumour characteristics in the entire cohort
of incident urothelial cancer, the TMA cohort and the
non-TMA cohort are shown in Table 2. As expected, the
vast majority of cases with known location (95.7%) were
located to the bladder. The proportion of pTa tumours
was higher in the non-TMA cohort, and pT1 tumours
were more frequent in the TMA cohort. The non-TMA
cohort included no tumours of stage T2 and above,
and all CIS cases were excluded from the TMA-
construction upfront, and therefore not included in the
correlation analyses. Age, sex, tumour location and smok-
ing habits did not differ between the TMA and the
non-TMA cohort. The distribution of patients and tumour
characteristics did not differ significantly between bladder
(n = 335) and non-bladder (n = 15) tumours (data not
shown), but, of note, there was a more equal distribution
of sex among the latter with 7 (46.7%) females and 8
(53.3%) males compared to 100 (29.9%) females and 235
(70.1%) males in the former.
The impact of clinicopathological factors on survival
during follow-up until Dec 31st 2012 is shown in
Table 3. In line with the expected, age at diagnosis,
T-stage and grade were independent prognostic fac-
tors. The prognosis for cases with Tis did not differTable 1 Distribution of established risk factors in
urothelial cancer cases and rest of cohort
Characteristics Rest of cohort Cases P
n (%) 27743 355
Age at baseline <0.001
Mean, median 58.1, 57.7 61.7, 62.4
(range) (44.5-73.6) (45.4-73.0)
Sex <0.001
Male 10817 (39.0) 246 (69.3)
Female 16925 (61.0) 109 (30.7)
Smoking habits <0.001
regularly 6549 (23.6) 125 (35.2)
occasionally 1239 (4.5) 23 (6.5)
Former smoker 9351 (33.7) 155 (43.7)
Never smoker 10592 (38.2) 52 (14.6)
missing 12
Unknown 5 0 5
Smoking habits 0.851
Regularly 125 (35.2) 99 (36.4) 26 (31.3)
Occasionally 23 (6.5) 15 (5.5) 8 (9.6)
Former 155 (43.7) 116 (42.6) 39 (47.0)
Never 52 (14.6) 42 (15.4) 10 (12.0)
¶Significance level after exclusion of CIS.significantly from pTa cases. Sex, tumour location and
smoking habits were not associated with survival.Distribution of ezrin expression in primary and metastatic
tumours
Following antibody optimisation and staining, ezrin ex-
pression could be evaluated in 263/272 (96.7%) primary
tumours and all 28 metastases. Lost cases were either a
result of complete tissue loss during IHC preparation or
an insufficient quantity of tumour tissue. Sample IHC
images are shown in Figure 2.
Table 3 Risk of death during follow-up according to
clinicopathological factors in the entire cohort
Factor Unadjusted Adjusted
n (events) HR (95% CI) n (events) HR (95% CI)
Age
Continuous 355 (166) 1.06 (1.04-1.09) 342 1.05 (1.03-1.08)
Gender
Female 109 (42) 1.00 103 (38) 1.00
Male 246 (124) 1.30 (0.92-1.85) 239 (122) 1.17 (0.81-1.70)
Stage
Ta 163 (63) 1.00 163 (63) 1.00
T1 97 (42) 1.61 (1.09-2.39) 97 (42) 1.16 (0.73-1.82)
T2 64 (48) 3.97 (2.71-5.82) 64 (48) 2.60 (1.60-4.23)
T3-4 6 (5) 13.13 (5.16-33.39) 6 (5) 7.81 (2.99-20.41)
Tis 12 (2) 0.38 (0.09-1.56) 12 (2) 0.42 (0.10-1.71)
Grade
Low 183 (65) 1.00 182 (64) 1.00
High 150 (96) 2.54 (1.85-3.48) 148 (94) 1.73 (1.14-2.62)
Location
Bladder 335 (158) 1.00 327 (153) 1.00
Other 15 (7) 0.84 (0.39-1.79) 15 (7) 0.87 (0.38-1.95)
Smoking
Regularly 125 (64) 1.00 120 (61) 1.00
Occasionally 23 (9) 0.63 (0.31-1.26) 23 (9) 0.69 (0.34-1.42)
Former 155 (71) 0.84 (0.60-1.18) 150 (71) 0.87 (0.61-1.25)
Never 52 (22) 0.81 (0.50-1.31) 49 (19) 0.86 (0.50-1.48)
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but not cytoplasmic ezrin expression was demonstrated
to be significantly downregulated in recurrent compared
to primary tumours.
Associations of ezrin expression with clinicopathological
characteristics
As shown in Table 4, analyses of the relationship between
cytoplasmic membranous staining and established clinico-
pathological factors revealed similar associations for mini-
mum, mean and maximum cytoplasmic and membranous
expression with clinicopathological factors. Significant as-
sociations were seen for both cytoplasmic and membran-
ous ezrin expression with more advanced T-stage (p =
0.004 and p < 0.001, respectively, for mean expression)
and high-grade tumours (p = 0.025 and p < 0.001, respec-
tively, for mean expression), but not with age, sex, tumour
location or smoking status.
Prognostic value of ezrin expression
CRT analysis determined optimal prognostic cut-offs at
0.988 for mean cytoplasmic and 0.538 for meanmembranous ezrin expression in relation to 5-year OS
(Additional file 1A and B). The same cutoffs were
obtained for OS (data not shown), and by ROC analysis
(data not shown).
As demonstrated in Figure 4, low cytoplasmic (logrank
p = 0.025) and membranous (logrank p < 0.001) ezrin
expression were associated with a significantly shorter
5-year OS. For cytoplasmic ezrin, the association with
survival was confirmed in univariable Cox regression
analysis (HR = 1.65; 95% CI 1.06-2.57), but did not
remain significant in multivariable analysis (HR = 1.11;
95% CI 0.70-1.77). As demonstrated in Table 5, the
prognostic value of membranous ezrin was confirmed in
both unadjusted (HR = 2.51, 95% CI 1.52-4.17) and ad-
justed (HR = 1.69, 95% CI 1.00-2.85), and these associa-
tions were slightly more significant when only bladder
tumours were included in the analysis. In bladder tu-
mours only, cytoplasmic ezrin expression was prognos-
tic in unadjusted but not in adjusted analyses (data not
shown). Neither cytoplasmic nor membranous ezrin
expression was prognostic in non-invasive (pTa, pT1)
tumours (data not shown). In tumours of pT2 stage and
beyond cytoplasmic ezrin was not prognostic (data not
shown), whereas loss of membranous ezrin was border-
line prognostic (univariable and multivariable HR =
2.72, 95% CI 0.97-7.63).
Similar associations with prognosis were seen for mini-
mum and maximum ezrin expression (data not shown).
Discussion
The present study provides a first clinicopathological de-
scription of incident urothelial cancers in the Malmö
Diet and Cancer Study up until 31st December 2010, a
total number of 355 tumours of which 272 have been
assembled in TMAs to provide a long-lasting platform
for studies into the molecular pathological epidemi-
ology (MPE) of urothelial cancer. The term MPE refers
to a multidisciplinary approach, initially proposed in
2010 [17], with the aim to investigate the relationship
between various exposure factors with molecular char-
acteristics of tumours, and particular progress has been
made in research related to colorectal cancer [18,19].
However, since urothelial cancer is a disease that af-
fects the entire urothelium and therefore particularly
strongly associated with the term “field cancerization”
[20,21], MPE research with an etiologically focused
approach to the field effect will also be highly relevant
in this type of cancer [22].
The distribution of patient and tumour characteris-
tics in the here described cohort of incident urothelial
cancers in the MDCS is in line with the expected. i.e. a
predominance of male sex, non-invasive (pTa) tu-
mours, and location to the bladder. The proportion of
males and smokers was also significantly higher in
Figure 2 Sample immunohistochemical images. Images representing A) a primary tumour with strong membranous and moderate
cytoplasmic ezrin expression in nearly 100% of cells, B) a primary tumour with negative membranous and weak, focally moderate cytoplasmic
staining (note strongly staining stromal lymphocytes). C) A primary tumour with negative membranous and focally weak cytoplasmic ezrin
expression and D) subsequent metastasis to the small intestine with negative membranous and moderate to strong cytoplasmic staining. E) A
primary tumour with moderate to strong membranous ezrin expression in approximately 25% and weak cytoplasmic staining in the majority of
cells and F) local recurrence with membranous ezrin expression in <5% and moderate to strong cytoplasmic ezrin expression in > 50% of cells.
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ing status was however associated with overall survival,
whereas both T-stage and tumour grade were strong
prognostic factors. Information on nodal stage was not
available, but since all tumours represented the first
diagnosis, the portion of cases having metastatic dis-
ease upfront should be negligible.
This paper also provides a validation of the prognos-
tic impact of ezrin expression in urothelial cancer. In
line with several recent studies [12-14], loss of ezrin
expression, in particular its membranous subcellular
location, was found to be associated with tumours
of more advanced T-stage and higher grade, and an
independent predictor of a reduced 5-year overall
survival. In this study, cytoplasmic ezrin expression
was also found to be associated with adverse tumour
characteristics and survival, although the prognostic
value did not remain independent of conventionalclinicopathological factors. This is in contrast to find-
ings from our previous study [14] and another recent
study [12], wherein cytoplasmic ezrin expression was
not found to be associated with neither clinicopatho-
logical factors nor survival. Of note, in thepresent
study, we used a more fine-tuned scoring system,
wherein the minimum and maximum expression of
ezrin was also taken into consideration. The clinico-
pathological correlates and prognostic impact were
however similar for all variables, with the overall best
correlations for the mean values. The application of
automated approaches may add additional value to
future validatory studies, in order to further determine
optimal prognostic cutoffs for ezrin expression in
urothelial carcinoma [23-25].
Of note, in contrast to previous studies related to
the prognostic values of ezrin, the present study also
included a small subset of non-bladder tumours. The
Figure 3 Distribution of ezrin expression in primary and
recurrent tumours. Bar charts visualizing the distribution of mean
A) cytoplasmic and B) membranous ezrin expression in primary and
recurrent tumours.
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not differ from bladder tumours, but there was a more
equal distribution of sexes, which is in line with previ-
ous findings [1]. Moreover, while the expression of
ezrin did not differ significantly by tumour location,
the prognostic impact of ezrin was slightly accentu-
ated in the subgroup analysis of bladder tumours only.
However, in light of the small number of cases with
non-bladder tumours available for analysis, this ob-
servation may well be coincidental. The distribution
of tumour stage and grade did not differ between
bladder and non-bladder UC in the present cohort,
but upper UC has been demonstrated to present with
slighty more advanced tumour stage and grade in lar-
ger series [26,27]. Tumour location was however not
prognostic, which is in line with findings from previ-
ous studies [28]. Nevertheless, it would inarguably be
of interest to further examine the prognostic value ofezrin expression in a larger series of non-bladder
urinary tract carcinoma.
Of note, only one case with non-bladder location
was a urethral cancer, a T2G3 tumour with partly
sarcomatoid differentiation in a male patient who
died within three months from diagnosis. This
tumour was not included in the TMA-analysis. Ure-
thral cancer is a rare disease, with somewhat differ-
ent aetiology and an often more aggressive clinical
course than UC of the bladder and upper urothelial
tract [29].
In this study, the prognostic value of ezrin was only
examined against 5-year overall survival. Previous
studies have however demonstrated an effect also on
progression-free survival [12] but not on the recurrence
rate [14]. Of note, in our previous paper, we did not find
an association between loss of ezrin expression and risk
of progression to muscle-invasive disease in pTa-pT1
tumours [14].
As a novel feature, the present paper also entails a
longitudinal study of ezrin expression, e.g. compari-
son of expression in primary and recurrent tumours,
the majority being local recurrences, in a small sub-
set of cases. Despite the small sample size, the find-
ing of a significant reduction of membranous ezrin
expression in recurrent tumours further supports the
increasing body of evidence demonstrating that loss
of ezrin is associated with tumour progression. In
contrast, there was no significant difference in cyto-
plasmic ezrin expression between primary and recur-
rent tumours. This finding may well be due to
chance, given the small sample size, but is also in
line with the observation of cytoplasmic ezrin seem-
ingly being more weakly associated with aggressive
tumour features. Nevertheless, future validatory stud-
ies on the prognostic value of ezrin expression in
UC should consider both its cytoplasmic and mem-
branous expression. The herein observed discrepancy
between ezrin expression in primary and metastatic
tumours also indicates that the metastases may be
the most suitable tissue for biomarker studies on
patients with clinically advanced UC. It will also be
relevant to examine the effects of neoadjuvant
chemotherapy on ezrin expression in tumours from
cystectomy specimens, to determine their suitability
for prognostication purposes [30].
The prognostic value of ezrin expression at the
mRNA level has not yet been determined, but im-
munohistochemistry has several advantages in that it
allows for assessment of biomarkers in a subcellular
and histological context, and can easily be incorpo-
rated into clinical protocols. Morever, there may well
be a prognostic disconcordance between mRNA and
protein levels of candidate biomarkers [31].
Table 4 Associations of cytoplasmic and membranous ezrin expression with clinicopathological parameters
Min cytoplasmic Mean cytoplasmic Max cytoplasmic Min membranous Mean membranous Max membranous




















≤ average 129 0.95, 1.00 0.332 1.03, 1.00 0.77 1.12, 1.00 0.77 0.46, 0.15 0.234 0.59, 0.37 0.423 0.72, 0.67 0.680
(49.0) (0.00-2.00) (0.00-2.13) 3 (0.00-2.25) 7 (0.00-2.50) (0.00-2.50) (0.00-2.50)
> average 134 0.90, 2.00 1.00, 1.00 1.12, 1.00 0.35, 0.10 0.52, 0.32 0.69, 0.50
(51.0) (0.00-2.00) (0.00-2.28) (0.00-2.90) (0.00-2.13) (0.00-2.25) (0.00-2.38)
Gender
Female 81 0.91, 1.00 0.781 1.00, 1.00 0.76 1.08, 1.00 0.89 0.46, 0.15 0.348 0.61, 0.62 0.362 0.77, 0.97 0.576
(30.8) (0.00-2.00) (0.00-2.28) 0 (0.00-2.90) 1 (0.00-1.70) (0.00-1.70) (0.00-2.38)
Male 182 0.92, 1.00 1.03, 1.00 1.13, 1.00 0.37, 0.10 0.53, 0.32 0.68, 0.51
(69.2) (0.00-2.00) (0.00-2.13) (0.00-2.25) (0.00-2.50) (0.00-2.50) (0.00-2.50)
T-stage
Ta 114 0.95, 1.00 0.005 1.05, 1.00 0.00 1.15, 1.00 0.00 0.50, 0.20 0.001 0.66, 0.59 <0.001 0.83, 0.90 <0.001
(43.3) (0.00-2.00) (0.00-2.15) 4 (0.00-2.80) 5 (0.00-2.13) (0.00-2.25) (0.00-2.38)
T1 84 0.99, 1.00 1.09, 1.05 1.19, 1.10 0.41, 0.15 0.62, 0.54 0.83, 0.72
(31.9) (0.00-2.00) (0.00-2.28) (0.00-2.90) (0.00-2.38) (0.00-2.38) (0.00-2.38)
T2-4 65 0.78, 0.95 0.88, 0.97 0.97, 1.00 0.21, 0.05 0.27, 0.07 0.34, 0.10
(24.7) (0.00-2.00) (0.00-2.00) (0.00-2.10) (0.00-2.50) (0.00-2.50) (0.00-2.50)
Grade
Low 133 1.01, 1.00 0.014 1.10, 1.00 0.02 1.19, 1.00 0.11 0.49, 0.15 0.008 0.66, 0.60 <0.001 0.84, 0.97 <0.001
(50.6) (0.00-2.00) (0.00-2.28) 5 (0.00-2.90) 4 (0.00-2.05) (0.00-2.50) (0.00-2.50)
High 130 0.83, 1.00 0.94, 1.00 1.04, 1.00 0.31, 0.10) 0.44, 0.20 0.57, 0.20
(49.4) (0.00-2.00) (0.00-2.00) (0.00-2.00) (0.00-1.90) (0.00-2.14) (0.00-2.38)
Location
Bladder 258 0.93, 1.00 0.934 1.03, 1.00 0.52 1.13, 1.00 0.51 0.40, 0.10 0.136 0.56, 0.37 0.040 0.71, 0.52 0.023
(98.1) (0.00-2.00) (0.00-2.28) 9 (0.00-2.90) 0 (0.00-2.50) (0.00-2.50) (0.00-2.50)
Other 5 0.82, 1.00 0.83, 1.00 0.84, 1.00 0.24, 0.00 0.24, 0.00 0.24, 0.00
(1.9) (0.00-1.10) (0.00-1.10) (0.00-1.10) (0.00-1.20) (0.00-1.20) (0.00-1.20)
Smoking status
Regularly 93 0.98, 1.00 0.384 1.07, 1.00 0.22 1.17, 1.00 0.15 0.42, 0.10 0.461 0.58, 0.50 0.300 0.75, 0.60 0.360
(35.4) (0.00-2.00) (0.00-2.13) 3 (0.00-2.25) 6 (0.00-2.50) (0.00-2.50) (0.00-2.50)
Occasionally 15 0.89, 1.00 1.05, 1.00 1.21, 1.00 0.43, 0.20 0.57, 0.55 0,72, 0.90
(5.7) (0.05-1.50) (0.08-1.55) (0.10-2.00) (0.00-1.20) (0.00-1.31) (0.00-1.50)
Former 113 0.85, 1.00 0.93, 1.00 1.01, 1.00 0.34, 0.10 0.49, 0.22 0.63, 0.35
(43.0) (0.00-2.00) (0.00-2.00) (0.00-2.10) (0.00-2.38) (0.00-2.38) (0.00-2.38)
Never 42 1.00, 1.00 1.12, 1.02 1.24, 1.05 0.49, 0.17 0.65, 0.56 0.83, 0.75
(16.0) (0.00-1.85) (0.00-2.28) (0.00-2.90) (0.00-1.75) (0.00-1.75) (0.00-2.00)
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This study provides a first description of the clinicopath-
ological characteristics of 355 incident urothelial cancers
in the Malmö Diet and Cancer Study up until 2010,
demonstrating the suitability of this cohort for molecular
pathological epidemiology research related to thesecancers. In addition, the value of ezrin expression as a
prognostic biomarker in urothelial cancer has been fur-
ther consolidated. Apart from an independent predictive
value with regard to five-year overall survival, membran-
ous ezrin expression was also demonstrated to be signifi-
cantly reduced in recurrent disease.
Figure 4 Kaplan-Meier estimates of bladder cancer specific survival and 5-year overall survival. Kaplan-Meier analysis of 5-year overall
survival according to low and high cytoplasmic and membranous ezrin expression.
Table 5 Relative risks of death within 5 years according to clinicopathological factors and membranous ezrin
expression in the entire cohort and in patients with bladder cancer
Entire cohort Bladder
Unadjusted Adjusted Unadjusted Adjusted
n (events) HR (95% CI) HR (95% CI) n (events) HR (95% CI) HR (95% CI)
Age
Continuous 263 (80) 1.05 (1.01-1.08) 1.03 (0.999-1.07) 258 (80) 1.05 (1.01-1.08) 1.03 (0.998-1.07)
Gender
Female 81 (23) 1.00 1.00 78 (23) 1.00 1.00
Male 182 (57) 1.10 (0.68-1.79) 0.94 (0.56-1.58) 180 (57) 1.06 (0.65-1.73) 0.91 (0.54-1.54)
Stage
Ta 114 (15) 1.00 1.00 112 (15) 1.00 1,00
T1 84 (22) 2.40 (1.24-4.62) 1.86 (0.86-4.02) 81 (22) 2.47 (1.28-7.68) 2.38 (1.23-4.60)
T2-4 65 (43) 8.83 (4.88-15.97) 5.46 (2.41-12.36) 65 (43) 8.68 (4.80-15.70) 7.12 (3.87-13.08)
Grade
Low 133 (20) 1.00 1.00 129 (20) 1.00 1.00
High 130 (60) 4.02 (2.43-6.68) 1.44 (0.71-2.92) 129 (60) 3.94 (2.37-6.54) 1.33 (0.65-2.73)
Smoking
Regularly 93 (30) 1.00 1.00 92 (30) 1.00 1.00
Occasionally 15 (4) 0.76 (0.27-2.17) 0.90 (0.31-2.58) 15 (4) 0.75 (0.26-2.14) 0.90 (0.31-2.57)
Former 113 (32) 0.86 (0.52-1.42) 0.73 (0.44-1.21) 110 (32) 0.88 (0.53-1.44) 0.74 (0.45-1.23)
Never 42 (14) 1.04 (0.55-1.95) 1.22 (0.64-2.33) 41 (14) 1.05 (0.56-1.99) 1.26 (0.66-2.39)
Ezrin
High 112 (20) 1.00 1.00 111 (20) 1.00 1.00
Low 151 (60) 2.51 (1.52-4.17) 1.69 (1.00-2.85) 147 (60) 2.58 (1.55-4.28) 1.74 (1.03-2.95)
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